JPMorgan Starts Synageva BioPharma (GEVA) at Overweight, Sets $50 Price Target
Tweet
Share
E-mailGet Alerts GEVA Hot Sheet
Price: $238.60 --0%
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
JPMorgan initiates coverage on shares of Synageva BioPharma (NASDAQ: GEVA) with an Overweight rating and $50 price target.
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $36.75 yesterday.
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $36.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
